Literature DB >> 32335868

Quality of life in hereditary neuropathy with liability to pressure palsies is as impaired as in Charcot-Marie-Tooth disease type 1A.

Bogdan Bjelica1, Stojan Peric2, Ivo Bozovic1, Milena Jankovic1, Marija Brankovic1, Aleksa Palibrk1, Vidosava Rakocevic Stojanovic1.   

Abstract

To date, only one study assessed quality of life (QoL) in patients with hereditary neuropathy with liability to pressure palsies (HNPP). We aimed to fill in this gap by investigating QoL in a cohort of patients with HNPP compared to Charcot-Marie-Tooth type 1A (CMT1A) patients, as well as to analyze sociodemographic and clinical features associated with QoL in HNPP. Eighteen genetically confirmed HNPP patients were age-and gender-matched with 18 CMT1A patients. SF-36 questionnaire was used to assess QoL. Medical Research Council (MRC) Sum Score, CMT Neuropathy Score (CMTNS), Overall Neuropathy Limitation Scale Score (ONLS), Falls Efficacy Score (FES), Visual Analog Pain Scale, Beck Depression Inventory (BDI) and Fatigue Severity Scale (FSS) were also used in our study. Although HNPP patients were less clinically impaired, no difference was observed in these two cohorts regarding SF-36 scores. Worse QoL in HNPP patients was associated with lower education (p < 0.01), physical work (p < 0.05), higher number of clinically affected nerves during the disease course (p < 0.01), worse MRC-SS score (p < 0.01), worse ONLS score (p < 0.01), and with more severe pain (p < 0.01), depression (p < 0.01), and fatigue (p < 0.01). Worse pain at the moment of testing appeared as a significant independent predictor of worse QoL in HNPP patients (β = - 0.93, p < 0.001). QoL was similarly impaired in patients with HNPP and patients with CMT1A. We identified different factors associated with QoL in HNPP, and many of these factors are amenable to treatment which is of special interest in these still incurable disease.
© 2020. Belgian Neurological Society.

Entities:  

Keywords:  Ability; Charcot–Marie–Tooth type 1A (CMT1A); Hereditary neuropathy with liability to pressure palsies (HNPP); Impairment; Quality of life

Mesh:

Year:  2020        PMID: 32335868     DOI: 10.1007/s13760-020-01355-w

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


  2 in total

1.  Relevance of anti-HNK1 antibodies in the management of anti-MAG neuropathies.

Authors:  Emilien Delmont; Shahram Attarian; Jean-Christophe Antoine; Stephane Paul; Jean Philippe Camdessanché; Aude-Marie Grapperon; Alexandre Brodovich; Jose Boucraut
Journal:  J Neurol       Date:  2019-05-14       Impact factor: 4.849

2.  Psychological distress in patients with Charcot-Marie-Tooth disease.

Authors:  P Vinci; P Gargiulo; M Panunzi; L Baldini
Journal:  Eur J Phys Rehabil Med       Date:  2009-09       Impact factor: 2.874

  2 in total
  3 in total

Review 1.  Mechanisms and Treatments in Demyelinating CMT.

Authors:  Vera Fridman; Mario A Saporta
Journal:  Neurotherapeutics       Date:  2021-11-08       Impact factor: 6.088

2.  Physical and Mental Aspects of Quality of Life in Patients With Charcot-Marie-Tooth Disease Type 1A.

Authors:  Vukan Ivanovic; Bogdan Bjelica; Aleksa Palibrk; Marija Brankovic; Ivo Bozovic; Ivana Basta; Andrija Savic; Vidosava Rakocevic Stojanovic; Aleksandra Kacar
Journal:  Front Neurol       Date:  2022-03-16       Impact factor: 4.003

3.  Anxiety and depression in Charcot-Marie-Tooth disease: data from the Italian CMT national registry.

Authors:  Marta Bellofatto; Alessandro Bertini; Irene Tramacere; Fiore Manganelli; Gian Maria Fabrizi; Angelo Schenone; Lucio Santoro; Tiziana Cavallaro; Marina Grandis; Stefano C Previtali; Isabella Allegri; Luca Padua; Costanza Pazzaglia; Daniela Calabrese; Paola Saveri; Aldo Quattrone; Paola Valentino; Stefano Tozza; Luca Gentile; Massimo Russo; Anna Mazzeo; Giuseppe Vita; Sylvie Piacentini; Chiara Pisciotta; Davide Pareyson
Journal:  J Neurol       Date:  2022-09-16       Impact factor: 6.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.